Form4insider filings, from the source

SEC Form 4 · accession 0001415889-18-001315

Vistagen Therapeutics, Inc. · VTGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mark Alan Smith
Officer — CHIEF MEDICAL OFFICER
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1,F2$3.49Aug 29, 2018D180,000D—Jun 19, 2026Common Stock180,0000D
Stock Option (Right to Buy)F2$1.50Aug 29, 2018A180,000A—Jun 19, 2026Common Stock180,000180,000D
Stock Option (Right to Buy)F3,F4$3.80Aug 29, 2018D80,000D—Nov 9, 2026Common Stock80,0000D
Stock Option (Right to Buy)F4$1.50Aug 29, 2018A80,000A—Nov 9, 2026Common Stock80,00080,000D
Stock Option (Right to Buy)F5,F6$1.96Aug 29, 2018D125,000D—Apr 26, 2027Common Stock125,0000D
Stock Option (Right to Buy)F6$1.50Aug 29, 2018A125,000A—Apr 26, 2027Common Stock125,000125,000D

Explanation of responses